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1. Introduction  
Gene therapy is a therapeutic method used to treat diseases by altering genes within a 
patient’s cells. The concept of gene therapy emerged as molecular biology evolved from the 
mere discipline of studying DNA molecules to the scientific art of virtually manipulating the 
genes of cells. Explosive worldwide research was conducted after the first introduction of 
the concept of gene therapy into the scientific community. The original aim was to directly 
modify patient genes through in vivo gene therapeutic approaches. However, DNA 
molecules introduced into the body by in vivo gene therapy are delivered at a very low 
frequency into terminally differentiated tissue cells, which typically do not have the 
capability of self-renewal (Tenenbaum et al., 2003). Because of the short-lived nature of in 
vivo gene therapy, a defective gene in patients is only temporarily corrected by in vivo gene 
therapy (Kaloss et al., 1999). The development of gene therapeutic methods in which the 
corrected patient gene remains permanently has been actively pursued.  
Ex vivo gene therapeutic methods have been considered as alternative options to gene 
therapy to overcome the short-lived nature of the corrected genes of in vivo gene therapy. In 
ex vivo gene therapy, the surgically removed adult stem cells, such as mesenchymal stem 
cells or hematopoietic stem cells, are typically cultured in a laboratory apparatus. The 
therapeutic DNA molecules are introduced into the isolated cells, and these transfected cells 
are then introduced into the patients. By using adult stem cells in ex vivo gene therapeutic 
methods, the corrected genes that are introduced are, in most cases, expressed permanently 
once they are corrected properly because the adult stem cells have the capability of self-
renewal (Dube & Denis, 1995; Muller-Sieburg & Sieburg, 2006; Tseng et al., 2006; Nehlin & 
Barington 2009). In ex vivo gene therapy, genetic manipulation is conducted in a lab outside 
of the body. However, normal somatic cells, including adult stem cells, do not propagate 
indefinitely and are vulnerable to epigenetic modification. Therefore, long-term cultures of 
somatic cells isolated from the body are very difficult to sustain (Beyer & Da sliva, 2006; 
Tonti & Mannello, 2008). This means that the long-term culture of adult stem cells in ex vivo 
gene therapy should be avoided as much as possible. Therefore, it is absolutely necessary to 
deliver therapeutic DNA molecules into isolated cells immediately with high efficiency.   
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In current gene transfer protocols, gene delivery vehicles containing therapeutic DNA 
molecules make only limited contacts with their target cells by passive diffusion, thereby 
limiting the chances of gene delivery. In our lab, we developed a very efficient method  
to deliver therapeutic genes to adult stem cells based on mechanical agitation (Park et  
al., 2009). 
In this method, mechanical agitation of the gene delivery vehicles containing cell 
suspensions increases the movement of gene delivery vehicles and target cells, resulting in 
an increase in contact between them. The application of our mechanical agitation method to 
the gene delivery process of ex vivo gene therapy, both in transfection and transduction, has 
increased the gene transfer efficiency more than that of any other previously known gene 
transfer protocol. 
2. Basic principles of current gene therapeutic approaches 
Gene therapy is classified as somatic gene therapy or germ line gene therapy. The 
application of current molecular genetic techniques used during the manipulation of 
transgenic or knock-out animals would definitely make gene therapy possible in virtually 
any type of germ line. However, all civilized societies in the world currently legally prohibit 
any attempts to genetically modify embryos. Thus far, gene therapy essentially implies 
somatic gene therapy. Compared to the easy genetic manipulation of embryonic stem cells, 
the genetic manipulation of somatic cells, including adult stem cells, is limited such that 
none of the somatic gene therapies are used practically thus far. Therefore, it is not 
surprising that the main quest of current gene therapy is to improve the efficiency of genetic 
manipulation in gene therapy, and the future success of gene therapy depends on the 
efficiency of genetic manipulation.   
Genetic manipulation in gene therapy can be achieved by two different approaches: direct 
genetic manipulation of somatic cells in the body and genetic manipulation of autologous 
cells outside of the body. These two different strategies for gene delivery are termed in vivo 
and ex vivo, respectively. In the in vivo strategy, therapeutic genes are delivered into cells in 
situ using a variety of vectors to produce therapeutic proteins in specific sites in the body. In 
ex vivo gene therapy, genetically modified autologous cells are surgically implemented into 
the body. The ex vivo and in vivo gene therapies both have positive and negative aspects. 
Although gene therapy has been a very hot topic in biomedical science for several decades, 
it is still in its infancy, and a number of hurdles must be overcome to achieve the practical 
application of gene therapy to patients. 
2.1 In vivo gene therapy 
In vivo gene therapy is a process in which a therapeutic gene is delivered through a vector 
directly into the target cells of patients to produce a therapeutic effect that prevents or treats 
diseases (Fig. 1). Theoretically, once an ideal gene delivery vehicle for a therapeutic gene 
transfer is developed, the in vivo gene therapy should involve a very simple procedure: the 
injection of a solution containing the gene delivery vehicle into the body. Because of this 
potentially easy treatment procedure in clinics, in vivo gene therapy is considered the 
preferred gene therapeutic method than ex vivo gene therapy. However, in vivo gene therapy 
has a basic and fundamental problem in the delivery of therapeutic genes to target cells: the 
low efficiency of gene transfer. 
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Fig. 1. Strategies for in vivo gene therapy. In Vivo gene therapy involves introduction of 
therapeutic DNA directly into the patient body. The DNA is introduced by cell–specific 
direct injection into tissue in need. Once inside the body and in contact with the specifically 
targeted cells, the inserted DNA is incorporated into the tissue cells where it encodes the 
production of the needed protein. 
The bottleneck in development of in vivo gene therapeutic methods has been the 
development of an efficient method for delivery of a therapeutic gene into the target cells of 
the body. The main reason for poor gene delivery efficiency in in vivo gene therapy is rooted 
to the nature of the body. The cells in the body are typically surrounded by an extracellular 
matrix that usually provides structural support to the cells in addition to performing 
various other important functions (Fig. 2). The main constituent of the body is the 
extracellular matrix, not cells (Suki & Jason, 2008). For example, collagen proteins, which are 
one of the components of the extracellular matrix, constitute approximately 25-35% of the 
protein content of the entire body, implying that the extracellular matrix occupies the main 
volume of the body (Khan et al., 2009). The injected gene delivery vehicles must pass 
through the extracellular matrix to deliver therapeutic proteins into target cells in in vivo 
gene therapy. However, because the extracellular matrix spatially occupies such a large 
portion of the body, there is an unsolvable limitation for efficient gene transfer in in vivo 
gene therapy.  
In addition to the low efficiency of gene delivery, in vivo gene therapy has another problem. 
The gene transfer vector is obligatorily exposed to the immune system of the body. This 
exposure causes an immune response that blocks gene delivery entirely. Overall, the 
potential immune response is another factor contributing to the low efficiency of gene 
delivery in in vivo gene therapy. Therefore, development of an ideal gene delivery vehicle 
for in vivo gene therapy is so extremely challenging that, until now, none of the in vivo gene 
therapeutic methods have not a satisfactory result.  
2.2 Ex vivo gene therapy 
In ex vivo gene therapy, cells are removed from a patient, maintained in culture to introduce 
a therapeutic gene into the cells, and then transplanted into the patient (Fig. 3). The role of 
the transplanted cells, which are genetically modified, is to deliver a recombinant gene  
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Fig. 2. Typical Anatomical Structure of Connective Tissue. A) The Confocal Microscopic 
Image of a Mouse Connective Tissue.  B) Schematic Illustration Depicting Extracellular 
Matrix. The extracellular matrix (ECM) is the extracellular part of animal tissue that usually 
provides structural support to the animal cells in addition to performing various other 
important functions. The extracellular matrix is the defining feature of connective tissue in 
animals. 
product into the patient’s body. The genetically modified cells are not required to 
reconstitute a particular organ or tissue for the purpose of reimplementation of the cells in a 
location where the cells were originally obtained. For example, genetically modified 
hepatocytes harvested from one liver lobe may be re-infused throughout any part of the 
liver of patients in ex vivo gene therapy.  
The main disadvantage of ex vivo gene therapy is that it requires the surgical removal of cells 
from the body and transplantation of the cells back to the body. These surgical steps are 
very painful. However, ex vivo therapy has several advantages over in vivo gene therapy. 
First, the efficiency of gene transfer into the targeted cells is very high compared to in vivo 
gene therapy because gene delivery is performed under controlled, optimized conditions. 
Second, the transduced cells can be enriched if the vector has a selectable gene marker. 
Third, the immunological side effects that are caused by gene delivery vehicles in in vivo 
gene therapy are usually minimized in ex vivo gene therapy.  
2.3 Ex-vivo gene therapy as a practical option to correct a defective gene permanently 
In vivo gene therapy introduces the therapeutic genes directly into the patient by 
intravascular injection. Because this approach is much simpler and less technically 
demanding than ex vivo gene therapy, which requires two surgical steps, the science of in 
vivo gene therapy has been preferentially developed. However, as discussed above, the 
nature of the mammalian body imposes innate, unsolved problems for in vivo gene therapy 
to achieve gene expression at therapeutically effective levels. The limitation of in vivo gene 
therapy for practical application is mainly due to low efficiency gene transfer. Because 
genetic manipulations are conducted in a lab in ex vivo gene therapy, the application of  
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Fig. 3. Strategies for Ex Vivo Gene Therapy. Ex vivo gene therapy is performed with the 
genetic alterations of patients target cells happening outside of the body in as culture. Target 
cells from the patient are infected with a recombinant virus containing the desired 
therapeutic gene. These modified cells are then reintroduced into the patient body, where 
they produce the needed proteins that correspond to the inserted gene. 
current molecular biological techniques can solve the low efficiency of gene transfer. Ex vivo 
gene therapy has the potential to ultimately solve this major problem of gene therapy, and it 
could be practically used in clinics. However, normal somatic cells, including adult stem 
cells, do not only propagate well in a typical cell culture environment and are also 
vulnerable to epigenetic modification (Islam et al., 2007; Martinez-Climent et al., 2006), 
requiring that the transfer of therapeutic genes to the isolated cells  be performed as soon as 
possible. Therefore, one of the key factors for the success of ex vivo gene therapy is to deliver 
therapeutic DNA molecules into isolated cells promptly with high efficiency. If these 
problems could be solved successfully, the ex vivo technique could be practically applied to 
patients in the near future. 
3. Current methods for gene delivery in ex vivo gene therapy 
As the name implies, the success of gene therapy depends on introducing therapeutic genes 
into target cells with high efficiency. Since Friedmann and Roblin formulated the concept of 
gene therapy in 1972 (Friedmann & Roblin, 1972), the biggest challenge in gene therapy has 
been the development of a method to deliver therapeutic genes to target cells with high 
efficiency. Although gene delivery in in vivo gene therapy is much easier than in ex vivo gene 
therapy, gene delivery into primary cells of in vitro cell cultures is also quite difficult. 
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Typical efficiencies of gene delivery to primary cells are 5-10% in most current methods (Cai 
et al., 2002; Ding et al., 1999; Eiges et al., 2001; Lakshmipathy et al., 2004; Peister et al., 2004), 
which is not high enough for satisfactory ex vivo gene therapy. Because of this, many 
different methods of gene delivery have been developed using primary cells for ex vivo gene 
therapy. Generally, gene delivery methods can be divided into two categories, viral and 
non-viral. 
3.1 Viral methods for gene delivery in ex vivo gene therapy 
Viruses have evolved specialized molecular mechanisms to efficiently transport their 
genomes into cells. Viral vectors have developed by taking advantage of the molecular 
mechanisms of the virus to deliver exogenous DNA into target cells. Currently, viral vectors 
are frequently used molecular biology tools for delivery of genetic material into cells of a 
living organism (in vivo) or in cell culture (in vitro). Viral vectors are tailored to their specific 
applications but share a key property. Because viral vectors are essentially created from 
pathogenic viruses, they are modified to minimize the pathogenic properties of the original 
viruses. This usually involves the deletion of a portion of the viral genome that is critical for 
viral replication. Such viral vectors can efficiently infect cells but once the infection has 
taken place, they cannot replicate. The viral vectors require helper genes to provide the 
missing proteins for production of new virions. Replication of viral vectors is usually 
conducted in packaging cells that were engineered with helper genes. Therefore, viral 
vectors can only replicate in packaging cells and exist solely to deliver exogenous DNA to 
target cells where the viral vector cannot replicate.  
Table 1 summarizes the types of viral vectors currently developed. In general, viral vectors 
are very efficient in terms of gene delivery into target cells. However, viral vectors have 
common problems including the following: (i) a limited DNA capacity, (ii) expression of 
viral genes, (iii) initiation of the antiviral immune response, (iv) reversion to a replication 
competent state and (v) decreasing expression over time. 
Viral vectors can be classified as DNA or RNA viral vectors. DNA viral vectors are derived 
from viruses such as adenovirus or herpes virus, which carry their genetic material in the 
form of DNA. Because these viral vectors persist as an extrachromosomal element after 
delivery into target cells, the viral vectors remain only temporarily. One advantage of the 
episomal presence of the vectors is that the gene expression level is high. Because exogenous 
genes cannot stay indefinitely, these vectors are not suitable for ex vivo gene therapy. 
Currently, these vectors are mostly used for in vivo gene therapy. 
Retroviral and lentiviral vectors are examples of RNA viral vectors that are replicated in 
target cells via reverse transcriptase to produce DNA from their RNA genomes. The DNA is 
then incorporated into the host's genome by an integrase. Thereafter, the virus replicates as 
part of the host cell's DNA, permitting long-term expression of the exogenous gene and 
ensuring transmission of the exogenous gene to the progeny of transduced cells. Therefore, 
these vectors are suitable for ex vivo gene therapy in which permanent gene expression is 
required in in vitro cell culture. These vectors are also widely used for in vivo gene therapy. 
3.2 Non-viral methods for gene delivery in ex vivo gene therapy 
Gene therapy was originally devised for the treatment of inherited genetic diseases, such as 
hemophilia and cystic fibrosis. However, the realm of gene therapy has been expanding to 
develop strategies for cancer, infectious diseases like HIV, and various complex diseases,  
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Vector 
Genetic 
material
Packaging 
capacity 
Tropism 
Inflammatory 
potential 
Vector 
genome 
forms 
Main 
Advantages 
Retrovirus RNA 8 kb 
Dividing 
cells 
Low Integrated
Persistent 
gene transfer  
in dividing 
cells 
Adenovirus dsDNA 7.5 kb 
Dividing 
and non-
dividing 
cells 
High 
Non-
integrated
Extremely 
efficient 
transduction 
of most 
tissues 
Adeno-associated 
virus 
ssDNA < 5kb 
Dividing 
and non-
dividing 
cells 
Low 
Non-
integrated 
(90%) 
Integrated 
(>10%)
Non-
inflammatory; 
non-
pathogenic 
Lentivirus RNA 8 kb 
Dividing 
and non-
dividing 
cells
Low Integrated
Persistent 
gene transfer 
in most 
tissues 
Herpes virus dsDNA > 30 kb 
Dividing 
and non-
dividing 
cells 
High 
Non-
integrated
Large 
packaging 
capacity; 
strong 
tropism for 
neurons 
Table 1. A comparison of different viral vectors used for gene therapy 
such as diabetes, dementia and hypertension. Genetic manipulations for these diseases are 
more complicated than genetic manipulations for the treatment of inherited genetic 
diseases. This means that current gene therapies need to deliver DNA, RNA, siRNA, or 
antisense sequences that alter gene expression within a specific cell population to 
manipulate cellular processes and responses. Viral vector-mediated gene deliveries are by 
far the most effective means of DNA delivery. However, the recombinant vector 
containing the therapeutic gene has to be packaged with viral coat proteins to make gene 
delivery possible, meaning that viral vector-mediated gene deliveries are limited to a 
DNA molecule of a certain size because the viral coat proteins have a limited DNA 
carrying capacity. Other than the physical limitation of viral vector-mediated gene 
deliveries, there are more limitations, such as immunotoxicity caused by viral coat 
proteins, restricted targeting of specific cell types, and recombination. Therefore, non-viral 
gene deliveries have been a very popular research topic, and many interesting and 
creative methods have been developed. The efficiency of gene delivery (i.e. transfection 
efficiency) is crucial to the success of non-viral gene deliveries. Various non-viral gene 
delivery methods currently developed could be classified into two groups: physical gene 
delivery methods and chemical gene delivery methods. 
3.2.1 Physical gene delivery methods 
Physical gene delivery methods are methods for transferring DNA molecules from the 
surrounding medium into cells. Naked DNA (i.e., an uncomplexed form of DNA) is used in 
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physical gene delivery methods. The easiest method to deliver genes into cells is to draw 
naked DNA into a microneedle and then inject the microneedle into cells to transfer the 
naked DNA directly to the cells. Though gene transfer efficiency by this method is very 
efficient, the method is very slow and laborious. The main drawback of this method is that 
microinjection can be only performed on one cell at a time, which means that this approach 
cannot be used for typical gene therapeutic approaches. The approach is limited to use for 
gene delivery into germ-line cells to produce transgenic organisms. 
Currently, the most popular physical methods for gene delivery into cells are 
electroporation and sonoporation. The cellular membrane is punctured by an electric pulse 
(electroporation) (Neumann et al., 1982) or ultrasonic wave (sonoporation) (Yizhi et al., 
2007). The pores in the cellular membrane are only temporarily formed, and DNA molecules 
pass through during the short period of time when the pores open. These methods are 
generally efficient and work well across a broad range of cell types. However, a high rate of 
cell death limits their use, especially in gene therapy. These methods are widely used for 
gene delivery of immortal cells in which cell viability is not a critical issue during gene 
transfer. 
Another popular method for physical gene delivery is the use of particle bombardment. In 
this method, gold particles (gene gun) (Gan et al., 2000) or magnetic particles 
(magnetofection) (Scherer et al., 2002) are coated with naked DNA. In the gene gun method, 
the DNA-coated gold particles are shot into the cell using high pressure gas, and the 
particles pass through the cellular membrane to introduce the particles inside the cells. In 
the magnetofection method, a magnet is placed underneath the tissue culture dish to attract 
DNA-coated magnetic particles. Then, the DNA-coated magnetic particles come into contact 
with a cell monolayer to introduce the particles inside the cells. These methods yield 
reasonably high efficiency gene transfers, but do not yield better efficiencies compared to 
other non-viral gene transfer methods, despite the requirement for expensive equipment. 
Also, it is quite difficult to control the DNA entry pathway, and the metal particles in the 
cells following gene transfer could negatively affect cells. Therefore, these methods are not 
widely used. 
3.2.2 Chemical gene delivery methods 
Because DNA cannot pass through cellular membranes alone, various chemicals have been 
designed to aid the transfer of therapeutic genes into cells. The chemicals used in chemical 
gene delivery function to enhance the stability of the DNA molecule, to increase the 
efficiency of cellular uptake and intracellular trafficking, or to alter the distribution of the 
transferred DNA in the cells. These methods are very successful in terms of transferring 
genes into cells and are currently the most widely used methods. Also, chemical gene 
delivery methods are the easiest and most effective among various non-viral gene delivery 
methods developed thus far. 
The most well-studied and effective approach for non-viral gene delivery is the use of 
cationic lipids. Positively charged cationic lipids naturally bind to negatively charged DNA 
in solution to condense DNA so that the DNA molecules and cationic lipids form complexes 
called lipoplexes. After lipoplexes are formed, the positively charged cationic lipids of the 
lipoplexes interact with cell membranes to allow cells to take up the lipoplexes by 
endocytosis. In typical cell physiology, endosomes that are formed as the result of 
endocytosis will fuse with lysosomes to degrade the lipoplexes containing the DNA. An 
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exogenous gene in the lipoplexes would not have a chance to be released into the cytoplasm 
for gene expression if the endosomes are stable. Therefore, helper lipids are added to form 
lipoplexes to facilitate the endosomal escape of the exogenous gene (Herringson et al., 
2009a, 2009b; Savva et al., 2005). This approach is very successful because it increases the 
transfection efficiency dramatically. There are various combinations of cationic lipids and 
helper lipids available. More than 40 products are commercially available for cationic lipid-
based gene delivery, including LipoTAXI (Agilent Technologies), LipofectaminTM (Invitrogen), 
NanoJuice® (Merck), Transfectam® (Promega), and LipoJet TM (SignaGen Laboratories). The 
cationic lipid-based gene delivery shows a very high transfection efficiency of up to 90 in in 
vitro cell culture. Because the cationic lipid-based lipoplexes are not stably maintained in the 
blood, these methods are best for ex vivo gene therapy. However, cationic lipid-based 
lipoplexes show a very poor transfection efficiency with primary cells, such as stem cells, 
indicating that new methodological developments are required for the practical application 
of ex vivo gene therapy.  
Other than cationic lipids, several different positively charged materials are used as a base 
material for non-viral DNA delivery, such as cationic polymers (Segura & Shea, 2001), 
cationic peptides consisting of poly-L-Lysine (D'Haeze et al., 2007; Mullen et al., 2000; 
Niidome et al., 1997), or other types of cationic proteins (De Lima et al., 1999; Jean et al., 
2009; Lam et al., 2004; Lee et al., 2003; Oliveira et al., 2009; Vighi et al., 2007). These 
approaches produce DNA carrying complexes that are more stable. However, the 
transfection efficiency of this method is not better than cationic lipid-based lipoplexes. 
Therefore, most of these methods are designed for in vivo gene therapy. 
4. Application of the mechanical agitation method to ex vivo gene therapy 
One of the main obstacles for the application of adult stem cells in ex vivo gene therapy is the 
low efficiency of gene transfer to these cells. For example, electroporation or transfection in 
mesenchymal stem cells yields 5-10% gene delivery efficiency (Cai et al., 2002; Ding et al., 
1999; Eiges et al., 2001; Lakshmipathy et al., 2004; Peister et al., 2004). Therefore, improved 
gene delivery methods would potentially be very beneficial for the practical application of 
ex vivo gene therapy in patient care. In current gene transfer protocols, virus particles or 
lipoplexes passively diffuse through the liquid culture medium to reach their target cells, 
which are layered on the bottom of a culture dish (Chuck & Palsson, 1996). Because the 
virus particles or lipoplexes contact the target cells by passive diffusion, increasing the 
chance of contact between virus particles or lipoplexes and their target cells would increase 
the chance of gene transfer and to promote higher transfer efficiencies. One simple way to 
increase contact between viruses or lipoplexes and target cells is through mechanical 
agitation. Based on this hypothesis, we developed a mechanical agitation method for 
retroviral transduction of primary cells or transfection by lipoplexes (Park et al., 2009). In 
this method, we simply implemented a step in which virus-containing or lipoplexes-
containing cell suspensions are agitated to increase the movement of viruses or lipoplexes 
and target cells with the purpose of generating more frequent contact between them. 
Suspended target cells have a better chance of making physical contact with virus particles 
or lipoplexes than adherent target cells because of the possibility for three-dimensional 
contact between the cells and viruses or lipoplexes. The simple addition of the mechanical 
agitation step to the conventional transduction or transfection protocol increased gene 
transfer efficiency two-fold above the current rates these protocols (Fig. 4). In the following 
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section, we describe one example of retroviral transduction using our mechanical agitation 
protocol. 
 
 
Fig. 4. A Typical Example of Application of Machanical Agitation Method to Transduction 
of EGFP-Carrying Retrovirus (Park et al., 2009). (A) The representative FACS plots of rat 
mesenchymal stem cells after transduction with Retro-EGFP using the static method (left 
panel), mechanical agitation of viruses with adhered cells (middle panel) and simultaneous 
mechanical agitation of retroviruses with suspended cells (right panel). (B) Numerical 
representation of the transduction efficiencies of EGFP retrovirus under the static protocol 
versus the new agitation protocol. The transduction efficiency is defined as the percentage 
of cells expressing EGFP as measured using FACSCalibur. The mean percentage of GFP-
positive cells is presented as the average of three independent transduction experiments 
(+/- SEM, n=3). 
4.1 Materials 
1. Packaging cell line PT67 (Clontech). 
2. pCAG-EGFP expression vector (Addgene, USA) and pMSCVneo retroviral vector 
(Clontech, USA). 
3. Lipofectamine 2,000 (Invitrogen). 
4. Rat mesenchymal stem cells (isolated by flushing the femurs of two-month-old female 
SD rats (Damool Bioscience Co., Korea). 
5. DMEM/ High glucose (Hyclone, USA) with 10% FBS (Hyclone), 2 mM L-glutamin 
(Invitrogen, USA), 100 μg/ml streptomycin, and 100 U/ml penicillin (Sigma, USA). 
6. Selection drug, G418 (Sigma) and Polybrene (Calbiochem, USA). 
7. Rat mesenchymal stem cell characterization kit (Millipore,USA). 
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8. TrypLE Express (Invitrogen). 
9. Carl Zeiss LSM510 Meta microscope.  
10. 0.45 μm cellulose acetate filter (Millipore). 
11. Rocker (SLS4, Seoulin, Korea). 
12. Incubator at 37°C under 5% CO2. 
13. 24-well plates and 96-well plates. 
14. E-Max micro-well reader (Molecular Devices, USA). 
15. Fluorescence microscope (TE2000-S, Nikon, Japan). 
16. FACSCalibur instrument (Becton Dickinson, USA). 
4.2 One example protocol of retroviral transduction into mesenchymal stem cells 
1. Trypsinize pure rat mesenchymal stem cells (0.1 ml/cm2) for 3 min at 37°C.  
2. Adjust the cell suspension to contain 5 × 105 cells/ml.  
3. Mix a 1 ml aliquot of the trypsinized rat mesenchymal stem cells directly with 1 ml 
virus stock in the presence of 6 μg/ml polybrene (Calbiochem, USA).  
4. Seed the mixing solution in a six-well plate (Falcon, USA).  
5. Mechanically agitate the plate containing the mixture of rat mesenchymal stem cells 
and virus on a rocker (SLS4, Seoulin, Korea) at 20 rpm for 50 min while incubating at 
37°C under 5% CO2.  
6. Incubate the plate at 37°C under 5% CO2 for 24 h. 
7. Replace the supernatant containing virus particles with fresh growth medium. 
8. Observe EGFP fluorescence in the transduced rat mesenchymal stem cells with a 
fluorescence microscope (TE2000-S, Nikon, Japan) after an 86 h incubation. 
5. Conclusion and prospect 
Since the first clinical trial of gene therapy in 1990, 1703 gene therapy clinical trials have 
been completed as of March of 2011 (http://www.wiley.com/legacy/wileychi/genmed 
/clinical/). However, little progress has been made since the first gene therapy clinical trial, 
and therefore, the Food and Drug Administration of the United States has not yet approved 
any human gene therapy for actual patient treatments. Although current gene therapy is still 
in the experimental stage, ex vivo gene therapeutic approaches show a great potential to treat 
monogenic genetic diseases as shown in the clinical trial results of adenosine deaminase 
deficiency and familial hypercholesterolemia (Cappelli et al., 2010 & Kassim et al., 2010). 
The clinical trial results of these diseases were encouraging to continually pursue ex vivo 
gene therapy. 
Primary cells, including adult stem cells, have limited self-renewal ability and are 
vulnerable to epigenetic modification (Dube & Denis, 1995; Muller-Sieburg & Sieburg, 2006; 
Tseng et al., 2006; Nehlin & Barington, 2009). The long-term culture of primary cells is not 
possible. Therefore, it is absolutely necessary to deliver therapeutic DNA molecules into 
isolated cells promptly with high efficiency. However, the transfer efficiency of exogenous 
DNA into primary cells is very low (Beyer & Da sliva, 2006; Tonti & Mannello, 2008). The 
gene transfer efficiency into primary cells is several fold less than those of cell lines in 
current gene transfer methods. This means that improvement of the transfer efficiency of 
exogenous DNA into primary cells is the first obstacle for the practical use of for ex vivo gene 
therapy. 
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The mechanical agitation method discussed here led to a higher efficiency gene transfer, 
either in transfection using lipoplexes or transduction, than that of any current static 
transduction method. This method can potentially be applied to a variety of current 
transduction or transfection protocols with slight adjustments to the agitation time and 
speed. We believe that this protocol will contribute to various ex vivo gene therapies and in 
vitro gene transfer experiments for primary cells. 
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